BP
REGN icon

BNP Paribas’s Regeneron Pharmaceuticals REGN Stock Holding History

BNP Paribas’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Buy
947
+7
+0.7% +$4.76K 0.02% 181
2026
Q1 		$726K Sell
940
-60
-6% -$45.9K 0.02% 193
2025
Q4 		$772K Buy
1,000
+134
+15% +$91K 0.02% 193
2025
Q3 		$487K Buy
866
+221
+34% +$125K 0.01% 195
2025
Q2 		$339K Sell
645
-1,093
-63% -$610K 0.01% 215
2025
Q1 		$1.1M Buy
1,738
+60
+4% +$41.3K 0.05% 160
2024
Q4 		$1.2M Sell
1,678
-55
-3% -$46.2K 0.01% 156
2024
Q3 		$1.82M Buy
1,733
+243
+16% +$270K 0.08% 110
2024
Q2 		$1.57M Sell
1,490
-296
-17% -$287K 0.08% 109
2024
Q1 		$1.72M Buy
+1,786
New +$1.7M 0.08% 111

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BNP Paribas's REGN Position: Q2 2026 in Review

BNP Paribas increased its Regeneron Pharmaceuticals (REGN) stake by 0.74% in Q2 2026, buying an estimated $4.76K and bringing the position to 947 shares worth $591K. The position accounts for 0.02% of the portfolio, ranked #181.

BNP Paribas first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.82M in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BNP Paribas held 947 shares of Regeneron Pharmaceuticals worth $591K as of Q2 2026.
  • BNP Paribas bought 7 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.76K.
  • Regeneron Pharmaceuticals made up 0.02% of BNP Paribas's portfolio in Q2 2026, its #181 holding.
  • BNP Paribas first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • BNP Paribas's Regeneron Pharmaceuticals position peaked at $1.82M in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BNP Paribas's 13F filing for Q2 2026, filed 13 Aug 2026.